NeuroDerm's Latest Clinical Data Accepted as Late Breaking News to the International Parkinson and Movement Disorder Society's 19th International Congress on June 14-18, 2015 in San Diego
09 juin 2015 07h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, June 9, 2015 (GLOBE NEWSWIRE) -- NeuroDerm (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, announced the company...
NeuroDerm to Ring The Nasdaq Stock Market Opening Bell on June 3, 2015
02 juin 2015 10h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, June 2, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that...
NeuroDerm Announces First Quarter 2015 Financial Results and Provides Corporate Update
27 mai 2015 07h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, May 27, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm CEO to Present at Jefferies 2015 Healthcare Conference on June 1, 2015
26 mai 2015 07h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, May 26, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that...
NeuroDerm to Host First Quarter 2015 Financial Results Conference Call on May 27, 2015
20 mai 2015 12h58 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, May 20, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that...
NeuroDerm Announces Lifting of FDA Clinical Hold on ND0612, a Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson's Disease
08 mai 2015 07h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, May 8, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that...
NeuroDerm Files Annual Report on Form 20-F for the Year Ended December 31, 2014
29 avr. 2015 07h30 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, April 29, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, announced today...
NeuroDerm Announces Fourth Quarter and 2014 Fiscal Year Financial Results and Provides a Corporate Update
02 avr. 2015 07h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, April 2, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm to Announce Updated Topline Results of Phase II Study of Continuous, Subcutaneously-Delivered Levodopa/Carbidopa for the Treatment of Parkinson's Disease at the 67th Annual Meeting of the American Academy of Neurology
01 avr. 2015 07h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, April 1, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, announced that...
NeuroDerm CEO to Present at Upcoming Investor Conferences
24 févr. 2015 07h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Feb. 24, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...